Literature DB >> 16816396

Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.

Kenneth N Agwuh1, Alasdair MacGowan.   

Abstract

The pharmacokinetics of tetracyclines and glycylcyclines are described in three groups. Group 1, the oldest group, represented by tetracycline, oxytetracycline, chlortetracycline, demeclocycline, lymecycline, methacycline and rolitetracycline is characterized by poor absorption after food. Group 2, represented by doxycycline and minocycline, is more reliably absorbed orally, while group 3, represented by the glycylcycline tigecycline, is injectable only, with an improved antibacterial spectrum compared with the tetracyclines. Though incompletely understood, the pharmacodynamic properties of the tetracyclines and glycylcyclines are summarized.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816396     DOI: 10.1093/jac/dkl224

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  200 in total

1.  Minocycline toxicity: case files of the University of Massachusetts medical toxicology fellowship.

Authors:  Matthew D Zuckerman; Katherine L Boyle; Christopher D Rosenbaum
Journal:  J Med Toxicol       Date:  2012-09

Review 2.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

3.  Low-molecular weight chitosan enhances antibacterial effect of antibiotics and permeabilizes cytoplasmic membrane of Staphylococcus epidermidis biofilm cells.

Authors:  Petra Kašparová; Martin Zmuda; Eva Vaňková; Olga Maťátková; Jan Masák
Journal:  Folia Microbiol (Praha)       Date:  2021-07-21       Impact factor: 2.099

Review 4.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

5.  Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess.

Authors:  Tammy Kielian; Nilufer Esen; Shuliang Liu; Nirmal K Phulwani; Mohsin M Syed; Napoleon Phillips; Koren Nishina; Ambrose L Cheung; Joseph D Schwartzman; Jorg J Ruhe
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

6.  In Vitro Assessment of Combined Polymyxin B and Minocycline Therapy against Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae.

Authors:  Dennis Huang; Brenda Yu; John K Diep; Rajnikant Sharma; Michael Dudley; Jussimara Monteiro; Keith S Kaye; Jason M Pogue; Cely Saad Abboud; Gauri G Rao
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

7.  Pharmacodynamics of doxycycline in a murine malaria model.

Authors:  Kevin T Batty; Angela S F Law; Verity Stirling; Brioni R Moore
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

Review 8.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Minocycline affects human neutrophil respiratory burst and transendothelial migration.

Authors:  Astrid Parenti; Boris Indorato; Sara Paccosi
Journal:  Inflamm Res       Date:  2016-10-18       Impact factor: 4.575

10.  Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.

Authors:  Eva Maria Staehli Hodel; Chantal Csajka; Frédéric Ariey; Monia Guidi; Abdunoor Mulokozi Kabanywanyi; Socheat Duong; Laurent Arthur Decosterd; Piero Olliaro; Hans-Peter Beck; Blaise Genton
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.